Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
NCT06423352Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of zilebesiran in hypertension (HTN), sponsored by Alnylam Pharmaceuticals. Started Jun 2024; status: completed.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06423352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423352.